Kornimate/medical-research-clean huggingface dataset:
brillouin microscopy used to evaluate corneal mechanical properties

Conditions: Map Dot Fingerprint Dystrophy; Post-penetrating Keratoplasty; Post-Descemet Membrane Endothelial Keratoplasty; Healthy Corneas; Fuchs Endothelial Dystrophy; Ost-Descemet Stripping Automated Endothelial Keratoplasty

Summary: this study aims to explore the mechanical properties of the cornea using a non-invasive imaging technique called brillouin microscopy. this innovative method measures corneal elasticity by detecting small shifts in light frequency, which occur due to interactions with acoustic waves in the tissue. these measurements can provide insights into how corneal stiffness is altered in various eye diseases or after surgery. the study includes 100 participants, divided into different groups: patients with fuchs' endothelial dystrophy (fed), map dot fingerprint dystrophy (mdfd), and those who have undergone corneal surgeries such as penetrating keratoplasty (pkp), descemet's stripping automated endothelial keratoplasty (dsaek), and descemet membrane endothelial keratoplasty (dmek). healthy individuals will also be studied as a control group. participants will first receive a standard eye exam, including a slit-lamp examination. then, brillouin microscopy will be used to measure the cornea's mechanical stiffness. additional tests include optical coherence tomography (oct), corneal topography and tomography, pachymetry (measuring corneal thickness), endothelial cell count, and intraocular pressure (iop) measurement. the purpose of this study is to better understand how diseases and surgeries affect corneal biomechanics. the researchers will also examine how well the brillouin measurements match with findings from other clinical imaging tests. the results may help improve diagnosis and treatment options for corneal disorders.


Eligibility criteria:
inclusion criteria: * written informed consent prior to surgery * patients aged 18 years and older * patients who have undergone one of the following corneal surgeries or are diagnosed with one of the following dystrophies: * penetrating keratoplasty (pkp) and no longer have sutures following pkp o descemet's stripping automated endothelial keratoplasty (dsaek) * descemet membrane endothelial keratoplasty (dmek) * fuchs' endothelial dystrophy (fed) * map dot fingerprint dystrophy (mdfd) * healthy controls: healthy eyes without any history of corneal diseases or surgeries exclusion criteria: any of the following will exclude a subject from the study: * patients with inadequate corneal imaging or corneal scarring that would impact results * patients with other corneal dystrophies or corneal diseases * patients with active ocular infections or inflammatory conditions * patients unable to undergo brillouin imaging adequately * patients that suffered an eye trauma according to their medical history * patients with fixational problems (e.g., head tremor) or with any medical condition that could interfere with the measurements * pregnancy (pregnancy test will be performed in women of reproductive age)
an integration of tai chi and repetitive transcranial magnetic stimulation for sleep disturbance in older adults

Conditions: Sleep Disturbance

Summary: the investigators designed an rct aimed at 1) exploring the effectiveness of combining tc with rtms for synergistically improving sleep disturbances in community-dwelling older adults, 2) investigating the mediating roles of arousal states as the underlying mechanism of the potential beneficial effects, and 3) evaluating the feasibility and safety to inform the clinical practice. the investigators hypothesized that integrating tc and rtms can affect the different dimensions of the arousal system to improve sleep disturbances with optimized clinical outcomes.


Eligibility criteria:
inclusion criteria: 1. classified with sleep disturbances (indications of poor sleep quality with a score \>5 in pittsburgh sleep quality index) 2. education level at primary or higher, and able to communicate in cantonese (3) no experience of mind-body exercising such as tc, qigong, or yoga within the past 6 months exclusion criteria: 1. serious visual or hearing difficulty 2. active suicidal ideation or self-harm behaviors 3. cognitive impairment (a score \<26 in the montreal cognitive assessment) 4. comorbid diagnoses such as mental disorders, organic brain syndrome, or intellectual disabilities 5. cardiac pacemaker, implanted medication pump, the intracranial implant (e.g., aneurism clips, shunts, stimulators, cochlear implants, or electrodes), or any other metal object within or near the head 6. receiving other treatments or participating in other clinical trials during the same period 7. current severe medical condition preventing physical exercise
a clinical trial to study the effects of two drugs, lycopene and prednisolone in patients with oral lichen planus

Conditions: Oral Lichen Planus

Summary: oral lichen planus (olp) is a common sub-acute, chronic inflammatory mucocutaneous disease.this study was evaluated the comparative efficacy of lycopene and prednisolone for the treatment of oral lichen planus. half of participants (total number of participants was twenty eight) were received lycopene and the other half were received prednisolone.

prednisolone and lycopene were produced remission of lesions in oral lichen planus patients, but they do so by different mechanisms. the main cause of oral lichen planus is still unknown. some authors advocate the disease appears to be a result of t-cell-mediated autoimmune responses in oral epithelial tissues. but, recent study suggests that increased reactive oxygen species (ros) and lipid peroxidation together with an imbalance in the antioxidant defense system may play a part in the generation of disease. lycopene exerts its antioxidant activity by physical and chemical quenching of free radicals and decreases free radicals-initiated oxidative reactions, particularly lipid peroxidation and dna oxidative damage, thereby preventing tissue damage. prednisone have both anti-inflammatory and immunosuppressant effects.it suppresses the inflammatory response by limiting the recruitment of inflammatory cells and inhibiting synthesis of pro-inflammatory products such as prostaglandins (pgs), leukotrienes (lts) and platelet activating factors (paf) by indirectly inhibiting phospholipase a2 and negative regulating cyclooxygenase (cox-2).

Eligibility criteria:
inclusion criteria: * subject had symptomatic i.e. burning sensation and/or pain secondary to oral lichen planus. * subject had clinically \& histo-pathologically diagnosed as oral lichen planus. * subject had not on any treatment for the same or treatment likely to modify their oral lichen planus (e.g. systemic steroids, antifungals, immunosuppressant's, anti-oxidant). exclusion criteria: * suffering from any systemic disease/s such as diabetes, hypertension, cardiovascular, respiratory system disease, renal dysfunction, liver disorders, malignancy, active peptic ulcer diseases, acute gastrointestinal diseases, anemia and glaucoma, etc. * suffering from serious or recurrent infection, immunodeficiency or hiv. * pregnant or breast feeding (including women who wish to be pregnant during the study period). * any other mucosal diseases or any other skin diseases which might be associated with oral lesions. * on any drug therapy which might be causes lichen planus like lesions. * known allergy or contraindication to study medications.

Keywords: antioxidant lycopene prednisolone
characterization of methylation patterns in lung cancer

Conditions: Lung Cancer

Summary: in this study the investigators will collect blood,sputum and saliva samples for characterization of methylation patterns in lung cancer.

lots of information about the relationship between changes in methylation patterns and various diseases are accumulated in recent years. characterization of methylation changes that occur in cancer may contribute to the development of methods for early detection of cancer by detecting cancer cells in liquids. early detection of such changes and their correlation examining different cancers may lead to a diagnostic tool for the early detection of cancers and improve the treatment of these patients. detection by molecular analysis can be a sensitive method and non-invasive early diagnosis of the disease in this study the investigators will collect blood,sputum and saliva samples for characterization of methylation patterns in lung cancer.

Eligibility criteria:
inclusion criteria: * patients with suspected lung tumor exclusion criteria: * patients who have active disease other than lung cancer during the sample collecting
the utility of cell-free dna methylation markers for hepatocellular carcinoma

Conditions: Cell-free Methylation Markers

Summary: the subjects of this study were patients with liver cancer diagnosed by physicians according to aasld clinical criteria or pathological biopsy. those who plan to receive systemic drug treatment for liver cancer in national taiwan university hospital include nexavar, lenvatinib, avastin, tecentriq, strivarga, cabometyx, cyramza, nivolunab, pembrolizumab, and yervoy. weak and uncooperative patients were excluded from blood tests, which were performed with full informed consent for relevant tumor markers (afp ,pivka-ii and methylation analysis). the data are then counted and compared.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with liver cancer by aasld clinical criteria or pathological slides patients planning to receive systemic drug therapy for liver cancer at national taiwan university hospital include nexavar, lenvatinib, avastin, tecentriq, strivarga, cabometyx, cyramza, nivolunab, pembrolizumab, and yevoy. 2. over 20 years old. 3. in the case of informed consent, willing to sign the consent form of the subjects. exclusion criteria: 1. patients who are weak and unable to cooperate with blood test. 2. kidney dysfunction, serum creatinine greater than 1.5 x unl (normal value) and no hemodialysis treatment, who are judged to be unwell for computed tomography or mri contrast agent injection.
a clinical investigation to follow the progress of exuding chronic venous leg ulcers using a non-bordered foam dressing

Conditions: Wounds; Wound of Skin; Wound Leg; Venous Leg Ulcer

Summary: the goal of this clinical trial to follow the progress of wounds in those with chronic venous leg ulcers while using a non-bordered foam dressing. the main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit. participants will be asked to wear the dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.

this investigation is designed as a prospective, open, multi-center, interventional, non-comparative investigation with the aim to follow chronic wound progression for 6 weeks according to local standard of care. wound progress is a summary endpoint of the total effect of treatment using the non-bordered foam dressing as the absorbent dressing and includes the changes in an objectively measured wound area and subjectively evaluated wound condition. the only included indication is venous leg ulcers (vlu). a total of n=20 participants will be recruited at up to 6 centers within the us and canada. there will be a total of seven (7) visits to the investigation site for participants during the treatment period: baseline, followed by weekly visits up to six (6) weeks post baseline. during visits, evaluations will be performed to assess wound progression and status, wound dressing properties, as well as subject pain, comfort, and quality of life. safety will be assessed at all visits. one target wound per participant will be included in this investigation.

Eligibility criteria:
inclusion criteria: * signed consent to participate (including consent for digital imaging) * adult aged ≥18 years * diagnosed with a chronic, exuding vlu * exudate amount moderate to large * wound size from 3 cm2 to 30 cm2, as determined by the clinician * abpi (within 3 months) \> 0.7. if abpi \> 1.4, then big toe pressure \> 60 mmhg is required or an alternative measurement verifying normal distal arterial flow * willing to be compliant with compression therapy exclusion criteria: * infected ulcer according to the judgment of the investigator defined as any wound condition requiring the prescription or continuation of systemic antibiotic therapy at enrollment * circumferential wound * known allergy/hypersensitivity to the materials of the dressing * use of wound fillers

Keywords: venous leg ulcer
pulmonary rehabilitation in interstitial lung diseases

Conditions: Interstitial Lung Disease

Summary: treatment in interstitial lung diseases (ild) is frequently ineffective. pulmonary rehabilitation (pr) is an excellent therapeutic option in another chronic lung diseases such as chronic obstructive pulmonary disease (copd). this prospective randomized controlled study aims to evaluate the short and long-term effects of pr in patients with ild. for this purpose, 60 ild patients will be randomly assigned to a pr or a control group. the investigators hypothesize that pr will improve exercise capacity, increase muscle force, reduce dyspnea and improve quality of life and daily life activities in ild patients.


Eligibility criteria:
inclusion criteria: * diagnosis of interstitial lung disease according to internationally established criteria * dyspnea on exertion * stable medical therapy * stable clinical condition at inclusion, with no infection or exacerbation in the previous 4 weeks exclusion criteria: * co-morbidities that do not allow exercise training (unstable angina, recent myocardial infarction or cerebrovascular accident, active cancer, severe orthopedic disorders). * life expectancy below 3 months

Keywords: ild
determining the etiology of febrile neutropenia using the karius sequencing-based infectious disease diagnostic assay

Conditions: Infection; Neutropenia

Summary: prospective, observational study at stanford university hospital comparing the karius infectious disease diagnostic sequencing assay to the final microbiologic diagnosis in patients with fever and neutropenia.


Eligibility criteria:
inclusion criteria: * 18 years of age * are or will be admitted to stanford university hospital for fever and neutropenia * neutropenia - an absolute neutrophil count of \<500 per cubic mm * documented fever or report of fever ≥38.3 or ≥38.0 on two episodes separated by at least one hour, resulting in hospitalization for febrile neutropenia exclusion criteria: * inability to understand instructions and comply with study-related procedures * any condition that in the opinion of the treating physician will prevent the subject from completing the study
clinical validation of the apollo daily disposable soft contact lenses

Conditions: Myopia

Summary: the purpose of this study was to confirm the design specifications of a test lens and validate its clinical performance.

this was a double-masked, randomized, bilateral two-day crossover, dispensing study design. subjects were randomized to wear the test lens or control lens bilaterally in random order and on a daily wear, single-use basis for a period of 2 days each.

Eligibility criteria:
inclusion criteria: * has had a self-reported oculo-visual examination in the last two years. * is at least 18 years of age and has full legal capacity to volunteer. * has read and understood the information consent letter. * is willing and able to follow instructions and maintain the appointment schedule. * is an adapted soft contact lens wearer, having worn contact lenses for a minimum 4 weeks prior to the study * has spectacle cylinder ≤1.00d in both eyes. * has spherical contact lens power requirement between -1.00d and -6.00d in both eyes. * has manifest refraction visual acuities (va) equal to or better than logmar equivalent of 20/20 in each eye. * wears cls in both eyes (monovision acceptable, but not monofit) * has clear corneas and no active ocular disease. * has not worn lenses for at least 12 hours before the examination * is willing to wear the study contact lenses for a minimum 8 hours on at least two consecutive days for each study pair. exclusion criteria: * has never worn contact lenses before. * has any systemic disease affecting ocular health. * is using any concomitant systemic or topical medications that will affect ocular health. * has any ocular pathology or severe insufficiency of lacrimal secretion (moderate to severe dry eyes) that would affect the wearing of contact lenses. * has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye. * has any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars. * is aphakic. * has undergone corneal refractive surgery. * is participating in any other type of eye-related clinical or research study.
effect of topical plexozome® levagen® spray on relief of post exercise knee joint pain

Conditions: Knee Joint Pain

Summary: this is a randomised, double-blind, placebo controlled, 2 arm parallel clinical trial to evaluate the effect of topical plexozome® levagen® spray on relief of post exercise knee joint pain in healthy adults compared to placebo over 4 weeks duration.


Eligibility criteria:
inclusion criteria: * adults over 20 years * generally healthy * able to provide informed consent * undertaking regular exercise * experiencing post exercise knee pain of at least 3 (on a 0-10 scale) at least 2 times in previous 4 weeks * agree not to change current diet and/or exercise frequency or intensity exclusion criteria: * serious illness( 1 ) e.g., mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as ms, kidney disease, liver disease or heart conditions * unstable illness( 2 ) e.g., diabetes and thyroid gland dysfunction * current malignancy (excluding bcc) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years * currently taking coumadin (warfarin), heparin, dalteparin, enoxaparin or other anticoagulation therapy * active smokers, nicotine use, alcohol( 3 ) or drug (prescription or illegal substances) abuse * allergic to any of the ingredients in the active or placebo formula * pregnant or lactating women * any condition which in the opinion of the investigator makes the participant unsuitable for inclusion footnotes ( 1 )a serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments. ( 2 )an unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. ( 3 )chronic past and/or current alcohol use (\>14 alcohol drinks/week)
chinese hospital acquired pneumonia collaboration network: epidemiology, diagnosis and treatment

Conditions: Hospital-acquired Pneumonia; Antibiotic Resistant Infection

Summary: the goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in china. the main purposes of this study are: 1. clarify the regional differences and changes over time in the pathogen spectrum and antibiotic resistance rate among hap patients in china; 2. build a continuously optimized nationwide hap pathogen and antibiotic resistance surveillance network; 3. identify the molecular epidemiology of common pathogens


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old. 2. meets the clinical diagnostic criteria for hap in the 2018 hap/vap guidelines. chest x-ray or ct shows new or progressive infiltrative shadows, consolidation shadows, or ground glass shadows, combined with 2 or more of the following 3 clinical symptoms, to establish a clinical diagnosis: 1) fever, body temperature\>38 ℃; 2) purulent airway secretions; 3) peripheral blood white blood cell count \>10 × 10\^9/l or \<4 × 10\^9/l. 3. having qualified evidence of responsible pathogen. on the basis of clinical diagnosis, one of the following conditions should be met simultaneously: 1) qualified lower respiratory tract secretions (neutrophil count \>25/low magnification field, epithelial cell count \ 2.5:1), pathogenic bacteria cultured through bronchoscopy anti pollution brush (psb), bronchoalveolar lavage fluid (balf), lung tissue or sterile body fluid, and consistent with clinical manifestations; 2) pathology, cytopathology, or direct microscopic examination of lung tissue specimens showing fungi and evidence of tissue damage; 3) the serum igm antibodies of atypical pathogens or viruses change from negative to positive, or the titers of specific igg antibodies in both acute and recovery phases show a 4-fold or more change. during the outbreak of respiratory viruses and with a history of epidemiological contact, respiratory secretions were tested positive for corresponding virus antigens, nucleic acid tests, or virus culture. 4. obtained informed consent exclusion criteria: 1. those who cannot understand and execute the investigation plan. 2. active pulmonary tuberculosis; 3. severely immunosuppressed patients: absolute neutrophil count \<0.5× 10\^9/l, cd4\<200/ml.
the effects of a long-lasting infusion of vasoactive intestinal peptide (vip) on headache, cranial hemodynamic and autonomic symptoms in healthy volunteers

Conditions: Headache Disorders

Summary: vasoactive intestinal peptide (vip) is a peptide of 28 amino acid residues that belongs to the glucagon/secretin superfamily of peptides. it is produced in different regions of the nervous system, including the brain, trigeminovascular system and several autonomic nerves. once released from neurons, it acts on vasoactive intestinal peptide receptor 1 (vpac1), vasoactive intestinal peptide receptor 2 (vpac2) and pituitary adenylate cyclase-activating polypeptide type i receptor (pac1), by mediating smooth muscle relaxation, vasodilation and water secretion. along with other neuropeptides, such as calcitonin gene-related peptide (cgrp) and pituitary adenylate cyclase-activating polypeptide (pacap), it is released from the trigeminal afferents and exerts a strong vasodilating activity on the cranial vasculature, sharing the activation of adenylate cyclase. especially, it shares 70% structure with pacap and acts on the same receptors. but, unlike it, vip cannot induce a long-lasting vasodilation and has a modest capability to induce migraine attacks. whether a long-lasting infusion of vip may induce a prolonged vasodilation in the cerebral vessels and migraine, as a twenty-minute infusion of pacap, is unknown.


Eligibility criteria:
inclusion criteria: 18-60 years. 50-90 kg. women of childbearing potential must use adequate contraception. exclusion criteria: headache less than 48 hours before the tests start all primary headaches daily consumption of drugs of any kind other than oral contraceptives pregnant or nursing women. a cardiovascular disease of any kind, including cerebrovascular diseases.